

Global Myasthenia Gravis Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G6A2503D925AEN.html>

Date: February 2023

Pages: 102

Price: US\$ 3,480.00 (Single User License)

ID: G6A2503D925AEN

Abstracts

Drug therapy for MG includes: (1) acetylcholinesterase inhibitors, (2) immunosuppressants, (3) immunomodulators. Introduce and gradually increase options based on international guidelines and the clinical and immunological characteristics of patients. Surgical treatments include (1) thymectomy, (2) median sternotomy and video-assisted thoracoscopic surgery, etc.

According to our (Global Info Research) latest study, the global Myasthenia Gravis Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Myasthenia Gravis Treatment market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Myasthenia Gravis Treatment market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Myasthenia Gravis Treatment market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Myasthenia Gravis Treatment market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Myasthenia Gravis Treatment market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Myasthenia Gravis Treatment

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Myasthenia Gravis Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amneal Pharmaceuticals, Inc., Astellas Pharma, Inc., Avadel Pharmaceuticals PLC, Bausch Health Companies Inc. and CSL Behring, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Myasthenia Gravis Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Medical Treatment

Operation Treatment

Market segment by Application

Hospital

Specialist Outpatient Clinic

Major players covered

Anneal Pharmaceuticals, Inc.

Astellas Pharma, Inc.

Avadel Pharmaceuticals PLC

Bausch Health Companies Inc.

CSL Behring

CuraVac, Inc.

Argenx SE

GlaxoSmithKline plc

Immunovant, Inc.

Mitsubishi Tanabe Pharma Corp.

Ra Pharmaceuticals, Inc.

Takeda Pharmaceutical Co., Ltd.

UCB Pharma

Valeant Pharmaceuticals International, Inc.

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Myasthenia Gravis Treatment product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Myasthenia Gravis Treatment, with price, sales, revenue and global market share of Myasthenia Gravis Treatment from 2018 to 2023.

Chapter 3, the Myasthenia Gravis Treatment competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Myasthenia Gravis Treatment breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales

quantity, consumption value and market share for key countries in the world, from 2017 to 2022. and Myasthenia Gravis Treatment market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Myasthenia Gravis Treatment.

Chapter 14 and 15, to describe Myasthenia Gravis Treatment sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Myasthenia Gravis Treatment
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global Myasthenia Gravis Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Medical Treatment
 - 1.3.3 Operation Treatment
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global Myasthenia Gravis Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Hospital
 - 1.4.3 Specialist Outpatient Clinic
- 1.5 Global Myasthenia Gravis Treatment Market Size & Forecast
 - 1.5.1 Global Myasthenia Gravis Treatment Consumption Value (2018 & 2022 & 2029)
 - 1.5.2 Global Myasthenia Gravis Treatment Sales Quantity (2018-2029)
 - 1.5.3 Global Myasthenia Gravis Treatment Average Price (2018-2029)

2 MANUFACTURERS PROFILES

- 2.1 Amneal Pharmaceuticals, Inc.
 - 2.1.1 Amneal Pharmaceuticals, Inc. Details
 - 2.1.2 Amneal Pharmaceuticals, Inc. Major Business
 - 2.1.3 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product and Services
 - 2.1.4 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.1.5 Amneal Pharmaceuticals, Inc. Recent Developments/Updates
- 2.2 Astellas Pharma, Inc.
 - 2.2.1 Astellas Pharma, Inc. Details
 - 2.2.2 Astellas Pharma, Inc. Major Business
 - 2.2.3 Astellas Pharma, Inc. Myasthenia Gravis Treatment Product and Services
 - 2.2.4 Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.2.5 Astellas Pharma, Inc. Recent Developments/Updates
- 2.3 Avadel Pharmaceuticals PLC

- 2.3.1 Avadel Pharmaceuticals PLC Details
- 2.3.2 Avadel Pharmaceuticals PLC Major Business
- 2.3.3 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Product and Services
- 2.3.4 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.3.5 Avadel Pharmaceuticals PLC Recent Developments/Updates
- 2.4 Bausch Health Companies Inc.
 - 2.4.1 Bausch Health Companies Inc. Details
 - 2.4.2 Bausch Health Companies Inc. Major Business
 - 2.4.3 Bausch Health Companies Inc. Myasthenia Gravis Treatment Product and Services
 - 2.4.4 Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.4.5 Bausch Health Companies Inc. Recent Developments/Updates
- 2.5 CSL Behring
 - 2.5.1 CSL Behring Details
 - 2.5.2 CSL Behring Major Business
 - 2.5.3 CSL Behring Myasthenia Gravis Treatment Product and Services
 - 2.5.4 CSL Behring Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.5.5 CSL Behring Recent Developments/Updates
- 2.6 CuraVac, Inc.
 - 2.6.1 CuraVac, Inc. Details
 - 2.6.2 CuraVac, Inc. Major Business
 - 2.6.3 CuraVac, Inc. Myasthenia Gravis Treatment Product and Services
 - 2.6.4 CuraVac, Inc. Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 CuraVac, Inc. Recent Developments/Updates
- 2.7 Argenx SE
 - 2.7.1 Argenx SE Details
 - 2.7.2 Argenx SE Major Business
 - 2.7.3 Argenx SE Myasthenia Gravis Treatment Product and Services
 - 2.7.4 Argenx SE Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.7.5 Argenx SE Recent Developments/Updates
- 2.8 GlaxoSmithKline plc
 - 2.8.1 GlaxoSmithKline plc Details
 - 2.8.2 GlaxoSmithKline plc Major Business

- 2.8.3 GlaxoSmithKline plc Myasthenia Gravis Treatment Product and Services
- 2.8.4 GlaxoSmithKline plc Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.8.5 GlaxoSmithKline plc Recent Developments/Updates
- 2.9 Immunovant, Inc.
 - 2.9.1 Immunovant, Inc. Details
 - 2.9.2 Immunovant, Inc. Major Business
 - 2.9.3 Immunovant, Inc. Myasthenia Gravis Treatment Product and Services
 - 2.9.4 Immunovant, Inc. Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 Immunovant, Inc. Recent Developments/Updates
- 2.10 Mitsubishi Tanabe Pharma Corp.
 - 2.10.1 Mitsubishi Tanabe Pharma Corp. Details
 - 2.10.2 Mitsubishi Tanabe Pharma Corp. Major Business
 - 2.10.3 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Product and Services
 - 2.10.4 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.10.5 Mitsubishi Tanabe Pharma Corp. Recent Developments/Updates
- 2.11 Ra Pharmaceuticals, Inc.
 - 2.11.1 Ra Pharmaceuticals, Inc. Details
 - 2.11.2 Ra Pharmaceuticals, Inc. Major Business
 - 2.11.3 Ra Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product and Services
 - 2.11.4 Ra Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.11.5 Ra Pharmaceuticals, Inc. Recent Developments/Updates
- 2.12 Takeda Pharmaceutical Co., Ltd.
 - 2.12.1 Takeda Pharmaceutical Co., Ltd. Details
 - 2.12.2 Takeda Pharmaceutical Co., Ltd. Major Business
 - 2.12.3 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Product and Services
 - 2.12.4 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.12.5 Takeda Pharmaceutical Co., Ltd. Recent Developments/Updates
- 2.13 UCB Pharma
 - 2.13.1 UCB Pharma Details
 - 2.13.2 UCB Pharma Major Business
 - 2.13.3 UCB Pharma Myasthenia Gravis Treatment Product and Services
 - 2.13.4 UCB Pharma Myasthenia Gravis Treatment Sales Quantity, Average Price,

Revenue, Gross Margin and Market Share (2018-2023)

2.13.5 UCB Pharma Recent Developments/Updates

2.14 Valeant Pharmaceuticals International, Inc.

2.14.1 Valeant Pharmaceuticals International, Inc. Details

2.14.2 Valeant Pharmaceuticals International, Inc. Major Business

2.14.3 Valeant Pharmaceuticals International, Inc. Myasthenia Gravis Treatment Product and Services

2.14.4 Valeant Pharmaceuticals International, Inc. Myasthenia Gravis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.14.5 Valeant Pharmaceuticals International, Inc. Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: MYASTHENIA GRAVIS TREATMENT BY MANUFACTURER

3.1 Global Myasthenia Gravis Treatment Sales Quantity by Manufacturer (2018-2023)

3.2 Global Myasthenia Gravis Treatment Revenue by Manufacturer (2018-2023)

3.3 Global Myasthenia Gravis Treatment Average Price by Manufacturer (2018-2023)

3.4 Market Share Analysis (2022)

3.4.1 Producer Shipments of Myasthenia Gravis Treatment by Manufacturer Revenue (\$MM) and Market Share (%): 2022

3.4.2 Top 3 Myasthenia Gravis Treatment Manufacturer Market Share in 2022

3.4.2 Top 6 Myasthenia Gravis Treatment Manufacturer Market Share in 2022

3.5 Myasthenia Gravis Treatment Market: Overall Company Footprint Analysis

3.5.1 Myasthenia Gravis Treatment Market: Region Footprint

3.5.2 Myasthenia Gravis Treatment Market: Company Product Type Footprint

3.5.3 Myasthenia Gravis Treatment Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Myasthenia Gravis Treatment Market Size by Region

4.1.1 Global Myasthenia Gravis Treatment Sales Quantity by Region (2018-2029)

4.1.2 Global Myasthenia Gravis Treatment Consumption Value by Region (2018-2029)

4.1.3 Global Myasthenia Gravis Treatment Average Price by Region (2018-2029)

4.2 North America Myasthenia Gravis Treatment Consumption Value (2018-2029)

4.3 Europe Myasthenia Gravis Treatment Consumption Value (2018-2029)

4.4 Asia-Pacific Myasthenia Gravis Treatment Consumption Value (2018-2029)

4.5 South America Myasthenia Gravis Treatment Consumption Value (2018-2029)

4.6 Middle East and Africa Myasthenia Gravis Treatment Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

5.1 Global Myasthenia Gravis Treatment Sales Quantity by Type (2018-2029)

5.2 Global Myasthenia Gravis Treatment Consumption Value by Type (2018-2029)

5.3 Global Myasthenia Gravis Treatment Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Myasthenia Gravis Treatment Sales Quantity by Application (2018-2029)

6.2 Global Myasthenia Gravis Treatment Consumption Value by Application (2018-2029)

6.3 Global Myasthenia Gravis Treatment Average Price by Application (2018-2029)

7 NORTH AMERICA

7.1 North America Myasthenia Gravis Treatment Sales Quantity by Type (2018-2029)

7.2 North America Myasthenia Gravis Treatment Sales Quantity by Application (2018-2029)

7.3 North America Myasthenia Gravis Treatment Market Size by Country

7.3.1 North America Myasthenia Gravis Treatment Sales Quantity by Country (2018-2029)

7.3.2 North America Myasthenia Gravis Treatment Consumption Value by Country (2018-2029)

7.3.3 United States Market Size and Forecast (2018-2029)

7.3.4 Canada Market Size and Forecast (2018-2029)

7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

8.1 Europe Myasthenia Gravis Treatment Sales Quantity by Type (2018-2029)

8.2 Europe Myasthenia Gravis Treatment Sales Quantity by Application (2018-2029)

8.3 Europe Myasthenia Gravis Treatment Market Size by Country

8.3.1 Europe Myasthenia Gravis Treatment Sales Quantity by Country (2018-2029)

8.3.2 Europe Myasthenia Gravis Treatment Consumption Value by Country (2018-2029)

8.3.3 Germany Market Size and Forecast (2018-2029)

- 8.3.4 France Market Size and Forecast (2018-2029)
- 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
- 8.3.6 Russia Market Size and Forecast (2018-2029)
- 8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Myasthenia Gravis Treatment Sales Quantity by Type (2018-2029)
- 9.2 Asia-Pacific Myasthenia Gravis Treatment Sales Quantity by Application (2018-2029)
- 9.3 Asia-Pacific Myasthenia Gravis Treatment Market Size by Region
 - 9.3.1 Asia-Pacific Myasthenia Gravis Treatment Sales Quantity by Region (2018-2029)
 - 9.3.2 Asia-Pacific Myasthenia Gravis Treatment Consumption Value by Region (2018-2029)
 - 9.3.3 China Market Size and Forecast (2018-2029)
 - 9.3.4 Japan Market Size and Forecast (2018-2029)
 - 9.3.5 Korea Market Size and Forecast (2018-2029)
 - 9.3.6 India Market Size and Forecast (2018-2029)
 - 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
 - 9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

- 10.1 South America Myasthenia Gravis Treatment Sales Quantity by Type (2018-2029)
- 10.2 South America Myasthenia Gravis Treatment Sales Quantity by Application (2018-2029)
- 10.3 South America Myasthenia Gravis Treatment Market Size by Country
 - 10.3.1 South America Myasthenia Gravis Treatment Sales Quantity by Country (2018-2029)
 - 10.3.2 South America Myasthenia Gravis Treatment Consumption Value by Country (2018-2029)
 - 10.3.3 Brazil Market Size and Forecast (2018-2029)
 - 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Myasthenia Gravis Treatment Sales Quantity by Type (2018-2029)
- 11.2 Middle East & Africa Myasthenia Gravis Treatment Sales Quantity by Application

(2018-2029)

11.3 Middle East & Africa Myasthenia Gravis Treatment Market Size by Country

11.3.1 Middle East & Africa Myasthenia Gravis Treatment Sales Quantity by Country

(2018-2029)

11.3.2 Middle East & Africa Myasthenia Gravis Treatment Consumption Value by Country (2018-2029)

11.3.3 Turkey Market Size and Forecast (2018-2029)

11.3.4 Egypt Market Size and Forecast (2018-2029)

11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)

11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

12.1 Myasthenia Gravis Treatment Market Drivers

12.2 Myasthenia Gravis Treatment Market Restraints

12.3 Myasthenia Gravis Treatment Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

12.5 Influence of COVID-19 and Russia-Ukraine War

12.5.1 Influence of COVID-19

12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Myasthenia Gravis Treatment and Key Manufacturers

13.2 Manufacturing Costs Percentage of Myasthenia Gravis Treatment

13.3 Myasthenia Gravis Treatment Production Process

13.4 Myasthenia Gravis Treatment Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Myasthenia Gravis Treatment Typical Distributors

14.3 Myasthenia Gravis Treatment Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Myasthenia Gravis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Myasthenia Gravis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Amneal Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors

Table 4. Amneal Pharmaceuticals, Inc. Major Business

Table 5. Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product and Services

Table 6. Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 7. Amneal Pharmaceuticals, Inc. Recent Developments/Updates

Table 8. Astellas Pharma, Inc. Basic Information, Manufacturing Base and Competitors

Table 9. Astellas Pharma, Inc. Major Business

Table 10. Astellas Pharma, Inc. Myasthenia Gravis Treatment Product and Services

Table 11. Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 12. Astellas Pharma, Inc. Recent Developments/Updates

Table 13. Avadel Pharmaceuticals PLC Basic Information, Manufacturing Base and Competitors

Table 14. Avadel Pharmaceuticals PLC Major Business

Table 15. Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Product and Services

Table 16. Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 17. Avadel Pharmaceuticals PLC Recent Developments/Updates

Table 18. Bausch Health Companies Inc. Basic Information, Manufacturing Base and Competitors

Table 19. Bausch Health Companies Inc. Major Business

Table 20. Bausch Health Companies Inc. Myasthenia Gravis Treatment Product and Services

Table 21. Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales Quantity

(K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 22. Bausch Health Companies Inc. Recent Developments/Updates

Table 23. CSL Behring Basic Information, Manufacturing Base and Competitors

Table 24. CSL Behring Major Business

Table 25. CSL Behring Myasthenia Gravis Treatment Product and Services

Table 26. CSL Behring Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 27. CSL Behring Recent Developments/Updates

Table 28. CuraVac, Inc. Basic Information, Manufacturing Base and Competitors

Table 29. CuraVac, Inc. Major Business

Table 30. CuraVac, Inc. Myasthenia Gravis Treatment Product and Services

Table 31. CuraVac, Inc. Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 32. CuraVac, Inc. Recent Developments/Updates

Table 33. Argenx SE Basic Information, Manufacturing Base and Competitors

Table 34. Argenx SE Major Business

Table 35. Argenx SE Myasthenia Gravis Treatment Product and Services

Table 36. Argenx SE Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 37. Argenx SE Recent Developments/Updates

Table 38. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors

Table 39. GlaxoSmithKline plc Major Business

Table 40. GlaxoSmithKline plc Myasthenia Gravis Treatment Product and Services

Table 41. GlaxoSmithKline plc Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 42. GlaxoSmithKline plc Recent Developments/Updates

Table 43. Immunovant, Inc. Basic Information, Manufacturing Base and Competitors

Table 44. Immunovant, Inc. Major Business

Table 45. Immunovant, Inc. Myasthenia Gravis Treatment Product and Services

Table 46. Immunovant, Inc. Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 47. Immunovant, Inc. Recent Developments/Updates

Table 48. Mitsubishi Tanabe Pharma Corp. Basic Information, Manufacturing Base and Competitors

Table 49. Mitsubishi Tanabe Pharma Corp. Major Business

- Table 50. Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Product and Services
- Table 51. Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 52. Mitsubishi Tanabe Pharma Corp. Recent Developments/Updates
- Table 53. Ra Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
- Table 54. Ra Pharmaceuticals, Inc. Major Business
- Table 55. Ra Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product and Services
- Table 56. Ra Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 57. Ra Pharmaceuticals, Inc. Recent Developments/Updates
- Table 58. Takeda Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
- Table 59. Takeda Pharmaceutical Co., Ltd. Major Business
- Table 60. Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Product and Services
- Table 61. Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 62. Takeda Pharmaceutical Co., Ltd. Recent Developments/Updates
- Table 63. UCB Pharma Basic Information, Manufacturing Base and Competitors
- Table 64. UCB Pharma Major Business
- Table 65. UCB Pharma Myasthenia Gravis Treatment Product and Services
- Table 66. UCB Pharma Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 67. UCB Pharma Recent Developments/Updates
- Table 68. Valeant Pharmaceuticals International, Inc. Basic Information, Manufacturing Base and Competitors
- Table 69. Valeant Pharmaceuticals International, Inc. Major Business
- Table 70. Valeant Pharmaceuticals International, Inc. Myasthenia Gravis Treatment Product and Services
- Table 71. Valeant Pharmaceuticals International, Inc. Myasthenia Gravis Treatment Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 72. Valeant Pharmaceuticals International, Inc. Recent Developments/Updates
- Table 73. Global Myasthenia Gravis Treatment Sales Quantity by Manufacturer

(2018-2023) & (K Units)

Table 74. Global Myasthenia Gravis Treatment Revenue by Manufacturer (2018-2023) & (USD Million)

Table 75. Global Myasthenia Gravis Treatment Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 76. Market Position of Manufacturers in Myasthenia Gravis Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022

Table 77. Head Office and Myasthenia Gravis Treatment Production Site of Key Manufacturer

Table 78. Myasthenia Gravis Treatment Market: Company Product Type Footprint

Table 79. Myasthenia Gravis Treatment Market: Company Product Application Footprint

Table 80. Myasthenia Gravis Treatment New Market Entrants and Barriers to Market Entry

Table 81. Myasthenia Gravis Treatment Mergers, Acquisition, Agreements, and Collaborations

Table 82. Global Myasthenia Gravis Treatment Sales Quantity by Region (2018-2023) & (K Units)

Table 83. Global Myasthenia Gravis Treatment Sales Quantity by Region (2024-2029) & (K Units)

Table 84. Global Myasthenia Gravis Treatment Consumption Value by Region (2018-2023) & (USD Million)

Table 85. Global Myasthenia Gravis Treatment Consumption Value by Region (2024-2029) & (USD Million)

Table 86. Global Myasthenia Gravis Treatment Average Price by Region (2018-2023) & (US\$/Unit)

Table 87. Global Myasthenia Gravis Treatment Average Price by Region (2024-2029) & (US\$/Unit)

Table 88. Global Myasthenia Gravis Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 89. Global Myasthenia Gravis Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 90. Global Myasthenia Gravis Treatment Consumption Value by Type (2018-2023) & (USD Million)

Table 91. Global Myasthenia Gravis Treatment Consumption Value by Type (2024-2029) & (USD Million)

Table 92. Global Myasthenia Gravis Treatment Average Price by Type (2018-2023) & (US\$/Unit)

Table 93. Global Myasthenia Gravis Treatment Average Price by Type (2024-2029) & (US\$/Unit)

Table 94. Global Myasthenia Gravis Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 95. Global Myasthenia Gravis Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 96. Global Myasthenia Gravis Treatment Consumption Value by Application (2018-2023) & (USD Million)

Table 97. Global Myasthenia Gravis Treatment Consumption Value by Application (2024-2029) & (USD Million)

Table 98. Global Myasthenia Gravis Treatment Average Price by Application (2018-2023) & (US\$/Unit)

Table 99. Global Myasthenia Gravis Treatment Average Price by Application (2024-2029) & (US\$/Unit)

Table 100. North America Myasthenia Gravis Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 101. North America Myasthenia Gravis Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 102. North America Myasthenia Gravis Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 103. North America Myasthenia Gravis Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 104. North America Myasthenia Gravis Treatment Sales Quantity by Country (2018-2023) & (K Units)

Table 105. North America Myasthenia Gravis Treatment Sales Quantity by Country (2024-2029) & (K Units)

Table 106. North America Myasthenia Gravis Treatment Consumption Value by Country (2018-2023) & (USD Million)

Table 107. North America Myasthenia Gravis Treatment Consumption Value by Country (2024-2029) & (USD Million)

Table 108. Europe Myasthenia Gravis Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 109. Europe Myasthenia Gravis Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 110. Europe Myasthenia Gravis Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 111. Europe Myasthenia Gravis Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 112. Europe Myasthenia Gravis Treatment Sales Quantity by Country (2018-2023) & (K Units)

Table 113. Europe Myasthenia Gravis Treatment Sales Quantity by Country

(2024-2029) & (K Units)

Table 114. Europe Myasthenia Gravis Treatment Consumption Value by Country (2018-2023) & (USD Million)

Table 115. Europe Myasthenia Gravis Treatment Consumption Value by Country (2024-2029) & (USD Million)

Table 116. Asia-Pacific Myasthenia Gravis Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 117. Asia-Pacific Myasthenia Gravis Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 118. Asia-Pacific Myasthenia Gravis Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 119. Asia-Pacific Myasthenia Gravis Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 120. Asia-Pacific Myasthenia Gravis Treatment Sales Quantity by Region (2018-2023) & (K Units)

Table 121. Asia-Pacific Myasthenia Gravis Treatment Sales Quantity by Region (2024-2029) & (K Units)

Table 122. Asia-Pacific Myasthenia Gravis Treatment Consumption Value by Region (2018-2023) & (USD Million)

Table 123. Asia-Pacific Myasthenia Gravis Treatment Consumption Value by Region (2024-2029) & (USD Million)

Table 124. South America Myasthenia Gravis Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 125. South America Myasthenia Gravis Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 126. South America Myasthenia Gravis Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 127. South America Myasthenia Gravis Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 128. South America Myasthenia Gravis Treatment Sales Quantity by Country (2018-2023) & (K Units)

Table 129. South America Myasthenia Gravis Treatment Sales Quantity by Country (2024-2029) & (K Units)

Table 130. South America Myasthenia Gravis Treatment Consumption Value by Country (2018-2023) & (USD Million)

Table 131. South America Myasthenia Gravis Treatment Consumption Value by Country (2024-2029) & (USD Million)

Table 132. Middle East & Africa Myasthenia Gravis Treatment Sales Quantity by Type (2018-2023) & (K Units)

Table 133. Middle East & Africa Myasthenia Gravis Treatment Sales Quantity by Type (2024-2029) & (K Units)

Table 134. Middle East & Africa Myasthenia Gravis Treatment Sales Quantity by Application (2018-2023) & (K Units)

Table 135. Middle East & Africa Myasthenia Gravis Treatment Sales Quantity by Application (2024-2029) & (K Units)

Table 136. Middle East & Africa Myasthenia Gravis Treatment Sales Quantity by Region (2018-2023) & (K Units)

Table 137. Middle East & Africa Myasthenia Gravis Treatment Sales Quantity by Region (2024-2029) & (K Units)

Table 138. Middle East & Africa Myasthenia Gravis Treatment Consumption Value by Region (2018-2023) & (USD Million)

Table 139. Middle East & Africa Myasthenia Gravis Treatment Consumption Value by Region (2024-2029) & (USD Million)

Table 140. Myasthenia Gravis Treatment Raw Material

Table 141. Key Manufacturers of Myasthenia Gravis Treatment Raw Materials

Table 142. Myasthenia Gravis Treatment Typical Distributors

Table 143. Myasthenia Gravis Treatment Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Myasthenia Gravis Treatment Picture

Figure 2. Global Myasthenia Gravis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Myasthenia Gravis Treatment Consumption Value Market Share by Type in 2022

Figure 4. Medical Treatment Examples

Figure 5. Operation Treatment Examples

Figure 6. Global Myasthenia Gravis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Figure 7. Global Myasthenia Gravis Treatment Consumption Value Market Share by Application in 2022

Figure 8. Hospital Examples

Figure 9. Specialist Outpatient Clinic Examples

Figure 10. Global Myasthenia Gravis Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 11. Global Myasthenia Gravis Treatment Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 12. Global Myasthenia Gravis Treatment Sales Quantity (2018-2029) & (K Units)

Figure 13. Global Myasthenia Gravis Treatment Average Price (2018-2029) & (US\$/Unit)

Figure 14. Global Myasthenia Gravis Treatment Sales Quantity Market Share by Manufacturer in 2022

Figure 15. Global Myasthenia Gravis Treatment Consumption Value Market Share by Manufacturer in 2022

Figure 16. Producer Shipments of Myasthenia Gravis Treatment by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021

Figure 17. Top 3 Myasthenia Gravis Treatment Manufacturer (Consumption Value) Market Share in 2022

Figure 18. Top 6 Myasthenia Gravis Treatment Manufacturer (Consumption Value) Market Share in 2022

Figure 19. Global Myasthenia Gravis Treatment Sales Quantity Market Share by Region (2018-2029)

Figure 20. Global Myasthenia Gravis Treatment Consumption Value Market Share by Region (2018-2029)

Figure 21. North America Myasthenia Gravis Treatment Consumption Value

(2018-2029) & (USD Million)

Figure 22. Europe Myasthenia Gravis Treatment Consumption Value (2018-2029) & (USD Million)

Figure 23. Asia-Pacific Myasthenia Gravis Treatment Consumption Value (2018-2029) & (USD Million)

Figure 24. South America Myasthenia Gravis Treatment Consumption Value (2018-2029) & (USD Million)

Figure 25. Middle East & Africa Myasthenia Gravis Treatment Consumption Value (2018-2029) & (USD Million)

Figure 26. Global Myasthenia Gravis Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 27. Global Myasthenia Gravis Treatment Consumption Value Market Share by Type (2018-2029)

Figure 28. Global Myasthenia Gravis Treatment Average Price by Type (2018-2029) & (US\$/Unit)

Figure 29. Global Myasthenia Gravis Treatment Sales Quantity Market Share by Application (2018-2029)

Figure 30. Global Myasthenia Gravis Treatment Consumption Value Market Share by Application (2018-2029)

Figure 31. Global Myasthenia Gravis Treatment Average Price by Application (2018-2029) & (US\$/Unit)

Figure 32. North America Myasthenia Gravis Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 33. North America Myasthenia Gravis Treatment Sales Quantity Market Share by Application (2018-2029)

Figure 34. North America Myasthenia Gravis Treatment Sales Quantity Market Share by Country (2018-2029)

Figure 35. North America Myasthenia Gravis Treatment Consumption Value Market Share by Country (2018-2029)

Figure 36. United States Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 37. Canada Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 38. Mexico Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 39. Europe Myasthenia Gravis Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 40. Europe Myasthenia Gravis Treatment Sales Quantity Market Share by Application (2018-2029)

Figure 41. Europe Myasthenia Gravis Treatment Sales Quantity Market Share by Country (2018-2029)

Figure 42. Europe Myasthenia Gravis Treatment Consumption Value Market Share by Country (2018-2029)

Figure 43. Germany Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 44. France Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 45. United Kingdom Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 46. Russia Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 47. Italy Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 48. Asia-Pacific Myasthenia Gravis Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 49. Asia-Pacific Myasthenia Gravis Treatment Sales Quantity Market Share by Application (2018-2029)

Figure 50. Asia-Pacific Myasthenia Gravis Treatment Sales Quantity Market Share by Region (2018-2029)

Figure 51. Asia-Pacific Myasthenia Gravis Treatment Consumption Value Market Share by Region (2018-2029)

Figure 52. China Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 53. Japan Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 54. Korea Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 55. India Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 56. Southeast Asia Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 57. Australia Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. South America Myasthenia Gravis Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 59. South America Myasthenia Gravis Treatment Sales Quantity Market Share by Application (2018-2029)

Figure 60. South America Myasthenia Gravis Treatment Sales Quantity Market Share

by Country (2018-2029)

Figure 61. South America Myasthenia Gravis Treatment Consumption Value Market Share by Country (2018-2029)

Figure 62. Brazil Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 63. Argentina Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 64. Middle East & Africa Myasthenia Gravis Treatment Sales Quantity Market Share by Type (2018-2029)

Figure 65. Middle East & Africa Myasthenia Gravis Treatment Sales Quantity Market Share by Application (2018-2029)

Figure 66. Middle East & Africa Myasthenia Gravis Treatment Sales Quantity Market Share by Region (2018-2029)

Figure 67. Middle East & Africa Myasthenia Gravis Treatment Consumption Value Market Share by Region (2018-2029)

Figure 68. Turkey Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 69. Egypt Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 70. Saudi Arabia Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 71. South Africa Myasthenia Gravis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 72. Myasthenia Gravis Treatment Market Drivers

Figure 73. Myasthenia Gravis Treatment Market Restraints

Figure 74. Myasthenia Gravis Treatment Market Trends

Figure 75. Porters Five Forces Analysis

Figure 76. Manufacturing Cost Structure Analysis of Myasthenia Gravis Treatment in 2022

Figure 77. Manufacturing Process Analysis of Myasthenia Gravis Treatment

Figure 78. Myasthenia Gravis Treatment Industrial Chain

Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 80. Direct Channel Pros & Cons

Figure 81. Indirect Channel Pros & Cons

Figure 82. Methodology

Figure 83. Research Process and Data Source

I would like to order

Product name: Global Myasthenia Gravis Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G6A2503D925AEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6A2503D925AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

